AKBA Stock Recent News

CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C.

There are so many new traders and investors entering the stock market today. But if you're brand new, you might not have a lot of money to invest or don't want to risk a whole lot while you're learning how to trade.

Investors seeking high-growth opportunities often turn their attention to penny stocks, which may have the potential to deliver substantial returns. The three potential high return penny stocks listed in the article possess the ingredients for explosive growth.

Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.

Penny stocks typically trade for less than $5 and generally belong to small companies often overlooked by mainstream investors. Yet, for those willing to navigate the inherent risks, these cheap stocks can offer a world of potential.

Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

CAMBRIDGE, Mass. , June 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m.

In the world of investment, penny stocks hold a unique position. Often priced at $5 per share or less, these are typically shares of small-cap companies that trade at relatively low prices.

Akebia Therapeutics Inc. is rated a Strong Buy due to its overly discounted revenue and strong prospects in the large Chronic Kidney Disease market. The company's valuation should be at least $716 million, more than 3x its current valuation, considering just Auryxia's revenue and the Healthcare Price/Revenue sector ratio. Risks include more total liabilities than total assets, cash flow negativity, stiff competition in the CKD drug market, and the possibility of FDA not approving vadadustat.